polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention: received two capsules of 1gr fish oil daily for 12 weeks. Intervention 2: control: received two capsules of placebo daily for 12 weeks.
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Women aged 18-35 Polycystic ovary syndrome on the basis of Rotterdam criteria No smoking
Exclusion criteria
Exclusion criteria: Revealed diabetes Hypothyroidism or hyperthyroidism Hyperprolactinemia Cushing's syndrome and adrenal and ovarian tumors Unwillingness to continue cooperation No regular use of the prescribed supplement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Testosterone. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: ELISA kit.;SHBG. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: ELISA kit.;Serum insulin. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Calculated with suggested formula.;Insulin sensitivity. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Calculated with suggested formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Gluthatione. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: In plasma sample will assessed by cholorimetric method. µmol/L.;Plasma total antioxidant. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: In plasma sample will assessed by cholorimetric method. µmol/L.;Malondialdehyde (MAD). Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: In plasma sample will assessed by cholorimetric method. µmol/L.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: In plasma sample will assessed by cholorimetric method. µmol/L.;Beck score. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;GHQ score. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;DASS-28 score. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Modified Ferriman Gallwey. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL-cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 12 week | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFereshteh Bahmani
Kashan University of Medical Sciences
Outcome results
None listed